Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
Executive Summary
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.
You may also be interested in...
Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It
Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, Scrip offers a baker's dozen of possible drugs.
Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It
Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, the Pink Sheet offers a baker's dozen of possible drugs.
Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It
Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, the Pink Sheet offers a baker's dozen of possible drugs.